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Reviewer's comments:
Reviewer 1
The review manuscript by Zadori et al. nicely presents a summary of glutamatergic 
dysfunctions observed in AD and suggests that ion channel blockers and GluN2B antagonists 
might be the targets for therapeutic interventions of AD. Overall, presentation in this review is
well done, and the included two figures are quite informative. However, the following minor 
points should be clarified and addressed for the publication in the Journal of Alzheimer's 
Disease:
1. The authors should cite more recent findings relevant to Aβ; direct/indirect effects on 
NMDA dysfunction in alterations of glutamatergic signaling in AD-molecular basis section 
(for example, please cite Kessel et al., PNAS 2013; Um et al., Nature Neuroscience 2012 etc).
The requested recent findings have been cited in the third section of the manuscript and 
the text has been supplemented with these recent data.
2. In pages 8 and 9, the typo "Kunitz protease inbitory domanin" should be corrected.
We corrected the typo at its occurrences.
Reviewer 2
This simple review mostly focuses on the glutamatergic system as a major perturbation in 
early AD. In spite of its simplicity, there are some aspects that can hardly be overlooked in a 
review such as:
1-There is an extensive description of AD-related pathology. However, it is not once 
mentioned that glutamatergic synapses (e.g. Scheff et al., 2006, Neurobiol Aging 27: 1372; 
Scheff et al., 2007, Neurology. 68: 1501) and glutamatergic markers (e.g. Kirvell et al., 2006, 
J Neurochem 98:939; Kashani et al., 2008, Neurobiol Aging 29: 1619; Cassano et al., 2012, 
Neurobiol Aging 33: 1121 Sokolow et al., 2012, Neurobiol Dis 45: 351; Mitew et al., 2013, 
Neurobiol Aging 34: 2341; Canas et al., 2014, Neuropharmacology 76: 51) are lost very early 
in AD patients and animal models of AD, a central aspect when considering glutamatergic 
alterations in AD. 
We processed the suggested references and built the essence of their data in the 
manuscript.
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2-In fact, AD neuropathology is shifting from overall markers characteristic of established 
AD to synaptic neuropathology (reviewed in e.g. Selkoe, 2002, Science 298: 789; Coleman et 
al., 2004, Neurology 63: 1155).
We agree with the reviewer’s opinion in respect of the fact that synaptic neuropathology
seems to be one of the most reliable predictors of cognitive dysfunctioning, and 
accordingly, the restoration of synaptic functioning would be the most important 
therapeutic aim. However, currently, the routine neuropathological diagnostic work up 
of Alzheimer’s disease relies on the semiquantitative assessment of the distribution of 
conventional disease markers. The state-of-the art assessment of synaptic 
neuropathology requires sophisticated methods such as electronmicroscopy and 
stereological synaptic count, which methodologies are however rather time-consuming 
and demanding, therefore are not likely to be good candidates for routine diagnostic 
work up. This issue indeed necessitates the development of more rapid methods in the 
future. In accordance with the reviewer’s emphasis, we aimed to draw more attention to 
the importance of synaptic neuropathology in revised version of our manuscript.
3-Probably more important than staging neuropathology would be to tackle a possibly novel 
aspect in this review: the staging of glutamatergic pathology (i.e. is plasticity affected before 
transmission and/or before synaptic pruning?). This is crucial to envisage glutamatergic-based
strategies as prophylactic or therapeutic.
The present short review mainly kept focus on the possibilities of therapeutic 
amelioration via targeting the glutamatergic neurotransmission system. However, we 
agree with the reviewer that the achievement of neuroprotection in AD is more complex 
than described here, mostly with keeping in mind the special aim of ‘synaptoprotection’.
Accordingly, in line with the response to the previous concern, in the revised version we 
included more data about synaptic pathology, paying attention to its therapeutic 
relevance as well.
4-The role of NMDA receptors is somehow over-simplified. For instance pre-synaptic 
NMDA receptors are simply forgotten in spite of increasing evidence for their presence and 
relevance in cortical circuits known to be affected in AD. Also, the role of NMDA receptors 
in spontaneous release-induced depression of evoked release is also not considered (e.g. 
Nosyreva et al., 2013, J Neurosci 33: 6990).
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We supplemented the manuscript with the short description of the requested issues.
5-A final aspect that is completely overlooked in this review is the possibility that non-
glutamatergic modulation systems known to control NMDA receptors might be ideal 
strategies to control NMDA receptor function (e.g. mGluR5, A1 or A2A adenosine receptors, 
amongst others).
The present short review mainly keeps focus on the agents that directly influence 
NMDA receptor-mediated neurotransmission. However, we agree with the reviewer that
indirectly acting agents cannot be totally neglected. Accordingly, we added a new short 
paragraph to the fourth section with the aim of drawing attention to this possibility as 
well.
Overall, there seems to be a need for some less narrowed views on NMDA receptor function 
and modulation to allow recognizing the required novelty and relevance in this review to 
recommend its publication in a prestigious journal such as JAD. 
We  express  our  thanks  to  the  Reviewers  for  their  valuable  remarks,  criticism  and
constructive advice. We hope that the Editor and the Reviewers will find our manuscript
worthy for publication in JAD, upon the changes made in the manuscript.
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The  impairment  of  glutamatergic  neurotransmission  plays  an  important  role  in  the
development  of  Alzheimer’s  disease  (AD).  The  pathological  process,  which  involves  the
production of  amyloid β peptides and hyperphosphorylated tau proteins, spreads over well
delineated neuroanatomical circuits. The gradual deterioration of proper synaptic functioning
(via GluN2A-containing N-methyl-D-aspartate receptors (NMDARs)) and the development of
excitotoxicity  (via  GluN2B-containing  NMDARs)  in  these  structures  both  accompany  to
disease  pathogenesis.  Although  one  of  the  most  important  therapeutic  targets  would  be
glutamate  excitotoxicity,  the  application  of  conventional  anti-glutamatergic  agents  could
result  in  further  deterioration  of  synaptic  transmission  and  intolerable  side-effects.  With
regard  to  NMDAR antagonists  with tolerable  side-effects,  ion  channel  blockers  with  low
affinity,  glycine site agents as well as specific antagonists  of polyamine site and GluN2B
subunit  may  come  into  account.  However,  in  the  mirror  of  experimental  data,  only  the
application of ion channel blockers with  pronounced voltage dependency, low affinity and
rapid unblocking kinetics (e.g. memantine) and  specific antagonists of the  GluN2B subunit
(e.g.  ifenprodil  and  certain  kynurenic  acid  amides)  resulted  in  desirable  symptom
amelioration. Therefore we propose that these kinds of chemical agents may have therapeutic
potential for present and future drug development.
Keywords: glutamate excitotoxicity, Alzheimer’s disease, neurodegeneration, 
neuroprotection, therapy, memantine, kynurenic acid amides
6
1. BACKGROUND
Alzheimer’s  disease  (AD)  is  a  progressive  neurodegenerative  disorder,  the  main  clinical
feature of which is dementia [1, 2]. Indeed, AD is the most common type amongst dementia
syndromes  [3];  it  is  responsible  for  60–80% of  the  cases  [4],  leading  to  a  considerable
socioeconomic burden. Although the clinical diagnosis can be set up during the disease course
in most of the cases, currently autopsy is always necessary for the definite diagnosis. The
main pathological hallmark of AD is the presence of neurofibrillary tangles (NFTs) and senile
plaques  in  specific  brain  areas  [5].  With  regard  to  the  involvement  of  dysfunctional
neurotransmission in disease pathogenesis, certain cholinergic and glutamatergic systems are
the most affected ones [6, 7].
The aim of this short review is to highlight some aspects of glutamatergic dysfunction in AD
and  to  discuss  some possibilities  of  pharmaceutical  interventions  via  targeting  the
glutamatergic system.
2. ALTERATIONS IN GLUTAMATERGIC SIGNALING IN ALZHEIMER’S 
DISEASE – PATHOLOGICAL BASIS
With regard  to  the  sensitivity  and specificity  for  the diagnosis  of  AD, the  Braak staging
system [5] gives the best accuracy (79%) amongst the neuropathological criteria systems [8].
This system classifies AD into stages mainly depending on the temporal evolution of NFTs
(composed of intracellular aggregates of hyperphosphorylated tau protein), but it also takes
into  account  the  loci  of  extracellular  amyloid  β  (Aβ)  deposits  in  the  brain.  The  system
distinguishes  between  the  following  stages:  transentorhinal/entorhinal  (stage  I,  II),  limbic
(stage III, IV) and neocortical (stage V, VI). This classification shows a good correlation with
the severity of dementia [9], though originally the pathological stages were established by
Braak  irrespectively  of  the  clinical  stage  of  the  dementia.  Certain  neuropathological
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investigations have special significance in the assessment of early stages of AD [10]. The
most important ones include the assessment of NFTs in the neurons of the second layer of the
entorhinal cortex in the slices of the inferior temporal lobe. The entorhinal cortex receives
converging polysynaptic glutamatergic inputs from the multimodal association cortices and
limbic  areas  including the hippocampal  formation,  while  it  projects  into the hippocampal
formation and back to the association cortices [11-13]. One of the main efferent glutamatergic
projections of the entorhinal cortex is the perforant pathway, which predominantly originates
from the second layer and serves as the main excitatory input of the hippocampal formation.
The  fourth  layer  of  the  entorhinal  cortex  in  turn  receives  excitatory  input  from  the
hippocampal formation. A significant decrease was observed in the neuronal number of the
fourth and especially the second layers of the entorhinal cortex in clinically very mild AD
[14]. Another study likewise demonstrated a considerable decrease in neuronal number and
volume of the entorhinal cortex (especially the second layer) and those of the cornu ammonis
(CA)1 region of the hippocampus in preclinical AD cases [15]. It is important to mention that
the presence of NFTs can also be observed in these early stages in the CA1-subiculum part of
the hippocampal formation and in the perirhinal cortex, inferior temporal gyrus, amygdala,
posterior part of the parahippocampal gyrus, the cholinergic basal forebrain and in the dorsal
raphe nuclei, but in a lesser extent compared to the second layer of the entorhinal cortex [16].
In next stages, almost all the limbic structures, notably the hippocampal formation (consisting
of the dentate gyrus, the hippocampus proper and the subiculum) and the amygdala become
considerably damaged [17] in addition to the more expressed involvement of the previously
described brain structures. As partially mentioned above, the main glutamatergic input of the
hippocampal formation comes from the second (toward the dentate gyrus (DG)) and the third
(toward the subiculum and CA1 sector of the hippocampus proper) layers of the entorhinal
cortex via the perforant and temporo-alvear pathways [18].  Scheff et al. [19] hypothesized
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that synaptic loss in the outer molecular layer (OML) of the DG would be responsible
for the transition from mild cognitive impairment to early AD. Total synaptic counts in
the  OML had a  significant  negative  correlation  with NFT density  in  the  entorhinal
cortex. Although there was a negative correlation between the individual’s Braak score
and  total  synaptic  number  in  the  OML,  this  association  was  not  significant  and
furthermore, this study did not find significant correlation of Braak staging with the
scores of any of the applied psychometric tests. However, a high positive correlation of
total synaptic number in the OML with the values of tests of cognitive functions such as
Mini Mental State Examination and delayed memory recall (one of the most sensitive
measures  of  hippocampal  function)  was  demonstrated  which  findings  suggest  that
synaptic loss would be one of the strongest predictive factors for cognitive decline. As a
part of the trisynaptic circuit, the information is transmitted further from the dentate gyrus via
intrahippocampal  association  pathways  (via  mossy  fibers  toward  the  CA3  sector  of  the
hippocampus, and then via Schaffer collaterals toward the CA1 sector) [20].  The synaptic
loss can also be observed in the CA1 sector of the hippocampus in mild AD cases [21].
The pyramidal cells of the CA1 sector predominantly innervate the subiculum, which projects
to  the  pre/parasubiculum (parts  of  the  subicular  complex  which  also  receives  neocortical
inputs likewise the entorhinal cortex), the amygdala, the fourth layer of the entorhinal cortex,
the anterior  and midline thalamic and mammillary nuclei  (via the fornix) [22].  Regarding
further parts of the Papez circuit, the information processes from the mammillary nuclei to the
anterior thalamic nuclei (via the mammilothalamic tract) and further to the cingulated gyrus
(via  the  anterior  thalamic  radiation)  and  to  the  presubiculum  (via  the  cingulum),  which
projects to the fourth layer of the entorhinal cortex [23]. The pre/parasubiculum also send
minor projections to the dentate gyrus [24]. It is also important to mention that parts of the
hippocampal formation in the two hemispheres are strongly interconnected via commissural
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fibers.  The  amygdaloid  complex,  which  consists  of  distinct  nuclei,  receives  inputs  from
multiple  brain  regions  via  several  kinds  of  transmitter  systems,  including  glutamatergic
pathways [25]. The major sources of sensory and polymodal information to the amygdala are
certain parts of the cerebral cortex, including the association and prefrontal cortices as well
[26]. The amygdala also forms reciprocal and strong connections with areas related to long-
term declarative  memory system,  including the  perirhinal  and entorhinal  cortices  and the
hippocampal  formation  [27].  Furthermore,  the  amygdaloid  complex  has  widespread
projections to certain cortical, subcortical and brainstem structures [25]. The key feature of
advanced stages of AD (stage V-VI) is the occurrence of severe destruction of neocortical
association areas as well [28, 29].  Although NFT pathology becomes expressed only in
advanced stages of AD in neocortical areas, the alteration in the level of some molecular
markers  of  synaptic  dysfunctioning  can  be  observed  even  in  early  stages  of  AD.
Accordingly,  vesicular  glutamate  transporter  (VGLUT)1  expression  is  found  to  be
decreased in the prefrontal, parietal and occipital and inferior temporal cortices, while it
was unaltered in the lateral temporal cortex [30-32]. With regard to the murine models
of AD, a significant reduction of VGLUT1 was observed in both the frontal cortex and
the hippocampus [33, 34]. The expression of VGLUT2 and synaptophysin was altered
only in the prefrontal cortex in human AD cases [30]. Loss of VGLUT1 and VGLUT2 in
the prefrontal cortex correlated with cognitive status even at early phases of cognitive
decline [30]. Although the typical spreading of neuropathological alterations over the above-
mentioned glutamatergic structures with strong connections (Fig. 1) can be well observed in
most  cases, limbic-predominant  and hippocampal-sparing subtypes of AD cases were also
reported [35].
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3. ALTERATIONS IN GLUTAMATERGIC SIGNALING IN ALZHEIMER’S 
DISEASE – MOLECULAR BASIS
The main culprits responsible for the disconnection of the previously delineated glutamatergic
networks would be the Aβ peptide and the tau protein [36]. Aβ1-42 aggregates are capable of
inducing  tau  hyperphosphorylation  [36]  and  promote  in  vitro tau  aggregation  in  a  dose-
dependent  manner  [37].  In  addition  to  NFTs,  soluble  tau  also  would  have  neurotoxic
properties [38]. Aβ can influence glutamatergic neurotransmission in several ways. Although,
under physiological concentrations, endogenous Aβ is necessary for proper neurotransmitter
release [39], in excess it weakens synaptic transmission affecting the synaptic vesicle pools
[40].  Accordingly,  Aβ  is  co-localized  in  glutamatergic  boutons  immunoreactive  for
VGLUT1  and  VGLUT2  in  post-mortem  AD  brains  [41]. Furthermore,  soluble  Aβ
oligomers induce the disruption of dendritic spines, resulting in severe neuropil damage
[42]. The degeneration of synapses and dendritic spines is one of the earliest feature of
AD  [43].  Glutamatergic  synapses  contain  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic  acid  receptors  (AMPARs)  and  N-methyl-D-aspartate  receptors
(NMDARs)  localized  on  dendritic  spines.  The  basal  synaptic  transmission  is  mainly
mediated by AMPARs. However, in  view of  receptor  dysfunction  in AD,  the NMDAR
would  be  the  major  site  of  Aβ  action,  and  in  turn,  NMDAR  activation  enhances  Aβ
production  [44].  A conventional  NMDAR is  composed  of  2  glycine  or  D-serine-binding
GluN1 and 2 glutamate-binding GluN2 (A-D) subunits, forming a heterotetramer. The GluN1
subunits  form the ion channel,  while  the  GluN2 subunits  have more  of  a  regulatory and
refining role. It has been shown that the GluN2B subunit-containing NMDARs predominate
at the extrasynaptic site [45], which preferential localization becomes more predominant by
the phosphorylation at Tyr1336 [46].  Oligomeric Aβ promotes Fyn kinase activation via
binding  to  the  post-synaptic  prion  protein  (PrPC),  resulting  in  the  increased
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phosphorylation of the GluN2B subunits at Tyr1472 [47]. This activation induces altered
NMDAR localization  with  destabilization  of  dendritic  spines  and the  loss  of  surface
NMDARs. It is important to mention that several other receptors are regulated by PrPC,
including metabotropic glutamate receptor  (mGluR) 1 and 5 [48].  The available  data
suggest that the activation of NMDARs at the synaptic site promotes neuronal survival, while
activation at the extrasynaptic site mediates neurotoxic effects [49]. However, some recent
findings suggest that the simultaneous activation of synaptic NMDARs are also necessary for
the initiation of cell death program [50]. So in brief, the inactivation of glutamatergic synaptic
transmission and the activation of that at the extrasynaptic sites would both accompany to the
pathomechanism of  AD.  Oligomeric  Aβ  impairs  long-term potentiation  (LTP;  a  form of
synaptic strengthening following brief, high frequency stimulation [51]) and enhances long-
term depression (LTD; a form of synaptic weakening following low frequency stimulation or
synaptic  inactivity  [52])  and  the  depotentiation  of  LTP,  thereby  causing  synaptic
dysfunctioning [53,  54].  Oligomeric  Aβ-induced internalization  of  synaptic  AMPARs  and
NMDARs  [55,  56]  and  non-apoptotic  caspase  activation  [57]  both  accompany  to  LTD
enhancement.  Although several forms of synaptic plasticity depend on NMDAR-driven
calcium  flux  [58],  some  recent  data  indicate  that  Aβ-mediated  synaptic  AMPAR
depression requires NMDAR activation in a metabotropic manner, i.e. without ion flow
via the NMDAR [59]. NMDARs also have an important role in spontaneous glutamate
release-induced depression of evoked neurotransmission, thereby influencing synaptic
efficacy  as  well  [60].  In  addition  to  the  demonstrated  alteration  of  glutamatergic
neurotransmission  via  postsynaptic  and  extrasynaptic  NMDARs  in  AD,  recent
experimental  data  provide  increasing  evidence  of  the  involvement  of  presynaptic
NMDARs in the enhancement of timing-dependent LTD, resulting in impaired memory
functions, which phenomenon may have implications in the development of cognitive
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decrement in AD [61-63]. With regard to caspase-3 activation, the increased activity of the
pyramidal  neurons  of  the  entorhinal  cortex,  the  subiculum  and  the  CA1-3  sector  of  the
hippocampus was found in early stages of AD [64]. The second layer of the entorhinal cortex
showed the highest activity. Aβ accumulation activates NMDARs at early stages of AD [65],
and  in vitro studies suggest that this  activation might  be mediated by GluN2B-containing
NMDARs [66]. It has been also demonstrated that NMDARs are connected to neuronal nitric
oxide synthase by a scaffolding protein PSD-95 (postsynaptic density protein of molecular
weight 95 kDa), which binds to the GluN2B subunit of the NMDAR [67]. Thus, PSD-95
would have an important role in the evocation of downstream excitotoxic events mediated by
GluN2B subunit-containing  NMDARs via  the  production  of  nitric  oxide  in  an  excessive
amount [68]. Recent data indicate that the activation of NMDARs by Aβ1-42 may be secondary
to  its  binding  to  postsynaptic  anchoring  proteins  such  as  PSD-95  [42].  Extrasynatptic
NMDAR activation triggers the increased production of Aβ due to the shift of amyloid β-
protein  precursor  (AβPP) production  from AβPP695 to Kunitz  protease  inbitory  domain-
containing isoforms with higher amyloidogenic potential [69]. This kind of positive feedback
leads  to  the  formation  of  a  vicious  circle  [70].  GluN2B-mediated  neurotransmission  also
seems to be involved in tau-induced neurotoxicity [71].  Tau phosphorylation causes tau
mislocalization  and  subsequent  synaptic  impairment  as  phosphorylated  tau  can
accumulate  in  dendritic  spines,  where  it  may  affect  the  synaptic  trafficking  and/or
anchoring of glutamate receptors [72]. The interaction of tau with fyn targets fyn to
dendritic spines, where it can exert the above-mentioned phosphorylation of GluN2B
subunit of NMDAR, thereby enhancing the excitotoxic process [73].  In addition to its
neuronal effects, Aβ also downregulates glutamate uptake capacity of astrocytes and thereby
induces a dysfunctional extracellular glutamate clearance [74]. Besides the elevated levels of
glutamate in the extracellular space, the presence of an energy impairment, as a consequence
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of  mitochondrial  dysfunction  and  oxidative  stress,  would  be  another  causative  factor  in
glutamate excitotoxicity, which leads to a partial membrane depolarization resulting in relief
of the Mg2+ blockade of the NMDAR channel and calcium overload [75].
4. THERAPEUTIC APPROACHES TARGETING THE GLUTAMATERGIC 
NEUROTRANSMISSION SYSTEM WITH A SPECIAL VIEW TO NMDA 
RECEPTORS IN ALZHEIMER’S DISEASE– PITFALLS AND POSSIBILITIES
The application of agents that completely blocks NMDAR activity has limited usefulness due
to severe clinical side-effects such as hallucinations, agitation, memory impairment, catatonia,
nausea,  vomiting,  a  peripheral  sensory  disturbance  and  sympathomimetic  effects  such  as
increased  blood  pressure [76,  77].  In  order  to  achieve  neuroprotection  by  targeting  the
NMDARs  in  AD,  the  best  therapeutic  strategy  could  be  the  normalization  of  synaptic
GluN1/GluN2A activity  and  the  abolishment  of  excitotoxicity  mediated  by  extrasynaptic
GluN1/GluN2B subunits.  In  view of  NMDAR antagonists  with  tolerable  side-effects,  ion
channel blockers with lower affinity, glycine site agents as well as specific antagonists of the
polyamine site or the GluN2B subunit may come into account (Fig. 2) [78]. Memantine (3,5-
dimethyladamantan-1-amine)  is  a  low affinity  open  channel  blocker,  which  preferentially
antagonizes excessively activated NMDARs without affecting physiological NMDAR activity
[79]. Accordingly, this substance has recently been demonstrated to selectively target mainly
GluN2B-containing  extrasynaptic  NMDARs [80],  i.e.  it  is  three times  more  potent  in  the
inhibition of calcium influx via GluN1/GluN2B than via GluN1/GluN2A subunit-containing
NMDARs [81]. Furthermore, memantine concentration-dependently inhibited the expression
of Kunitz protease inbitory domain-containing AβPP isoforms as well as neuronal production
and release of Aβ [69, 82]. Accordingly, memantine is a widely applied medicament in the
treatment of moderate-advanced stages of AD with beneficial  effects as regards language,
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memory, praxis and communicational dysfunctions as well as the activity of daily living [83].
Although  memantine  has  some  potential  side-effects  such  as  somnolence,  weight  gain,
confusion, hypertension, nervous system disorders and falling [84], to date this is the only
commercially available NMDAR antagonist in the treatment of AD. In summary, the good
effect/side-effect  profile  would  be  explained  by its  pronounced  voltage  dependency,  low
affinity and rapid unblocking kinetics, which properties make the restoration of the desired
signal-to-noise ratio in glutamatergic neurotransmission available [85].
Kynurenic acid (KYNA; produced by kynurenine aminotransferases (KATs)), a side-product
of  the  main  pathway  of  the  tryptophan  metabolism,  can  influence  glutamatergic
neurotransmission  at  several  levels  [86]  and  exerted  neuroprotective  effects  in  several
paradigms  [86-90].  On  the  one  hand,  KYNA  can  exert  wide-spectrum  endogenous
antagonism  of  ionotropic  excitatory  amino  acid  receptors  [91],  mainly  targeting  the
strychnine-insensitive glycine-binding site on the GluN1 subunit of the NMDA receptor [92].
This  action  requires  relatively  high  (~10–20  μM)  concentrations  of  KYNA  under
physiological conditions [93]; the basal extracellular concentration of KYNA in rats (15–23
nM) [94, 95] is  far  below the  required level  to  directly  interfere  with glutamate  receptor
functions. Accordingly, only excessive elevation of the KYNA level could be accompanied
by adverse effects in rats, such as reduced exploratory activity, ataxia, stereotypy, sleeping,
and respiratory depression, while there was only a slight effect on the learning ability [96].
However, human post mortem analyses revealed elevated levels of KYNA in the striatum and
hippocampus of AD patients [97], which alteration is rather suggested to accompany to the
cognitive dysfunction in AD than to exert  compensatory protective role.  Accordingly,  the
achievement of lowering brain KYNA levels by knocking out one of its producing enzyme
(KAT II) resulted in the improvement of cognitive functions in mice [98]. With regard to the
mechanisms  of  influencing  glutamatergic  transmission,  on  the  other  hand,  KYNA  non-
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competitively  blocks  the  alpha7-nicotinic  acetylcholine  receptors  [99],  thereby  inhibiting
glutamate release at the presynatptic site [100]. This blockade can be already effective in high
nanomolar concentrations (IC50 = ~7 μM), and can as well influence hippocampus-dependent
cognitive functions [101]. In addition to the multiplex receptor  antagonism, recent studies
showed  that  KYNA  is  capable  of  facilitating  AMPA  receptor  responses  in  nanomolar
concentrations [102, 103]. The significance of this phenomenon is not really known, yet.
The selective inhibition of GluN2B subunit-containing NMDARs could be another successful
strategy  in  the  amelioration  of  neurodegenerative  processes  [104].  Ifenprodil  (α-(4-
hydroxyphenyl)-β-methyl-4-benzyl-1-piperidineethanol)  is  a  synthetic  negative  allosteric
modulator  of  such  of  receptors,  with  relatively  high  affinity  (IC50 =  ~  150  nM)  [105].
Ifenprodil binding seems to interact with polyamine binding in a negative allosteric manner,
i.e. it can inhibit the potentiation of NMDAR currents evoked by certain polyamines [106,
107].  It  has  a  considerably  good  side-effect  profile:  mouth  dryness,  nausea,  headache,
palpitations could only be observed. Accordingly, several derivatives, including Ro 25-6981
([R-(R*,S*)]-α-(4-hydroxyphenyl)-β-methyl-4-benzyl-1-piperidinepropanol),  have  been
synthesized with the aim of presenting lead compounds in pharmaceutical development in the
field  of  neurodegenerative  disorders  [104].  With  regard  to  AD,  Aβ-induced  endoplasmic
reticulum and oxidative stress was prevented by ifenprodil [108]. Furthermore, this substance
and Ro 25-6981 also prevented the Aβ-mediated inhibition of LTP in rodent hippocampal
slices [109-112]. Indeed, Ro 25-6981 abolished LTD enhancement and learning impairment
in rats as well [113]. Evotect’s EVT 101, another GluN2B antagonist, which has been shown
to penetrate into the human brain, was well tolerated in a double-blind, 4-week phase Ib study
(http://www.evotec.com).
A possible pharmaceutical modification of KYNA is amidation at the carboxyl moiety [114,
115]. The resulting KYNA amides may be of special interest since they have been shown to
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preferentially act on GluN2B subunit-containing extrasynaptic NMDARs [116]. This feature
may also offer the opportunity to establish an extracellular concentration that is capable of
inhibiting the tonic extrasynaptic NMDAR currents without impairing synaptic glutamatergic
neurotransmission.  Accordingly,  one  of  the KYNA amide  compounds  synthesized  by our
group,  N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide  hydrochloride
exerted protective effects both in the four-vessel occlusion model of cerebral ischemia (rats;
[117]) and in the N171-82Q transgenic mouse model of HD [118].
Finally,  in addition to directly influencing NMDARs, it is important to mention that
there are some indirect regulators of NMDAR functioning, targeting of which can be
used  as  alternative  therapeutic  approaches  in  the  amelioration  of  glutamatergic
dysfunction in AD. These targets include some metabotropic glutamatergic receptors
[119] and certain adenosine receptors [120, 121].
5. CONCLUSION
Although more and more details are being revealed regarding the pathomechanism of AD, the
recent  therapeutic  strategies  are  restricted  only  to  few  pharmaceutical  agents.  The
glutamatergic  system is presumed to be the major altered neurotransmitter  system in AD;
therefore, there is a great need for the development of pharmakons targeting this system with
acceptable side-effect profile. From this respect,  ion channel blockers with lower affinity as
well  as  GluN2B subunit  specific  antagonists  might  be the  most  promising  candidates  for
future AD therapy.  Although the present short review kept focus on the possibilities of
therapeutic amelioration via targeting the glutamatergic neurotransmission system with
special attention to NMDARs, it should be noted that achieving neuroprotection in AD –
especially in terms of ‘synaptoprotection’ – is a complex issue, with pharmacological
17
targets  and  approaches  we  could  not  touch  in  detail,  but  have  already  been
comprehensively discussed by others [122, 123].
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8. FIGURE CAPTIONS
Figure 1. The schematic depiction of the predominant connections between the affected 
glutamatergic brain areas in Alzheimer’s disease. (CA: cornu ammonis)
Figure 2. Some possibilities of influencing glutamatergic dysfunctioning in Alzheimer’s 
disease. (α7-nAChR: alpha7-nicotinic acethylcholine receptors, KYNA: kynurenic acid, 
NMDAR: N-methyl-D-aspartate receptor, ▲: glutamate, the thickness of the lines represents 
the extent of inhibition, while dashed lines refers to possible mechanism of action)
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